Source Paper
Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation
Belén G. Ramírez, Cristina Blázquez, Teresa Gómez del Pulgar, Manuel Guzmán, María L. de Ceballos
Journal of Neuroscience • 2005
Intracerebroventricular WIN55,212-2 Administration in Rats
Objective: To assess whether intracerebroventricular administration of synthetic cannabinoid WIN55,212-2 prevents β-amyloid-induced microglial activation, cognitive impairment, and loss of neuronal markers in rats
This is a Intracerebroventricular WIN55,212-2 Administration in Rats protocol using rat as the model organism. The procedure involves 5 procedural steps, 2 materials. Extracted from a 2005 paper published in Journal of Neuroscience.
Model and subjects
rat • Not specified • unknown • Not specified • Not specified
Study window
Estimated timing pending
Core workflow
Intracerebroventricular Administration • β-Amyloid Treatment • Cognitive Assessment
Primary readouts
- Microglial activation status
- Cognitive impairment
- Loss of neuronal markers
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Intracerebroventricular Administration
Administer WIN55,212-2 intracerebroventricularly to rats
Note: This is the primary intervention in the in vivo experiment
View evidence from paper
“Intracerebroventricular administration of the synthetic cannabinoid WIN55,212-2 to rats prevent β-amyloid-induced microglial activation, cognitive impairment, and loss of neuronal markers”
β-Amyloid Treatment
Treat rats with β-amyloid peptide following WIN55,212-2 administration
Note: Timing and dosage of β-amyloid administration not specified in provided text
View evidence from paper
“Intracerebroventricular administration of the synthetic cannabinoid WIN55,212-2 to rats prevent βA-induced microglial activation, cognitive impairment, and loss of neuronal markers”
Cognitive Assessment
Assess cognitive impairment in treated rats
Note: Specific cognitive tests not detailed in provided text
View evidence from paper
“prevent βA-induced microglial activation, cognitive impairment, and loss of neuronal markers”
Microglial Activation Analysis
Evaluate microglial activation status in brain tissue
Note: Methods for assessing microglial activation not specified in provided text
View evidence from paper
“Intracerebroventricular administration of the synthetic cannabinoid WIN55,212-2 to rats prevent βA-induced microglial activation”
Neuronal Marker Assessment
Measure loss of neuronal markers in brain tissue
Note: Specific neuronal markers and measurement methods not detailed in provided text
View evidence from paper
“prevent βA-induced microglial activation, cognitive impairment, and loss of neuronal markers”